CHICAGO (GenomeWeb) – Children's Hospital Los Angeles will implement Edico Genome's Dragen Bio-IT platform to help the hospital expand genome-based testing for children with cancer and various genetic disorders, Edico said today.
Children's LA has already validated the Dragen Germline pipeline, Edico Genome said. The pediatric facility will now adopt other elements of the Bio-IT platform. This includes reviewing the Dragen Somatic pipeline for whole-exome sequencing of cancer samples and the RNA Seq pipeline for fusion detection, according to the technology vendor.
"This new platform will enable us to expand our growing suite of clinical tests and will also enhance our clinical research," Jaclyn Biegel, director of the CHLA Center for Personalized Medicine, said in a statement.
"With the ability to process terabytes of sequences in days rather than months, we can more effectively mine genomic data from our own patients, as well as cohorts of patients from large consortia such as the International Cancer Genome Consortium," Biegel added. "Significant strides in our understanding of pediatric cancer genetics will in turn empower our own genetic test offerings."
San Diego-based Edico today also debuted the Dragen Clinical Genomics Information System, software designed to help clinical laboratories develop sequencing-based tests.